Trial Profile
Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Inflammatory bowel diseases; Plaque psoriasis; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 08 Feb 2018 Status changed from not yet recruiting to completed.
- 02 Jan 2017 New trial record